Idioma:

Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer

TAKIGAWA, N ; KIURA, K ; TABATA, M ; SHINKAI, T ; HIRAKI, S ; TAKEMOTO, M ; KANAZAWA, S ; MATSUO, K ; TANIMOTO, M ; SEGAWA, Y ; WATANABE, Y ; KAMEI, H ; MORITAKA, T ; SHIBAYAMA, T ; UEOKA, H ; GEMBA, K ; YONEI, T

British journal of cancer, 2006-11, Vol.95 (9), p.1142-1144 [Periódico revisado por pares]

Basingstoke: Nature Publishing Group

Texto completo disponível

Citações Citado por

Enviar para

Título:
Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer
Autor: TAKIGAWA, N ; KIURA, K ; TABATA, M ; SHINKAI, T ; HIRAKI, S ; TAKEMOTO, M ; KANAZAWA, S ; MATSUO, K ; TANIMOTO, M ; SEGAWA, Y ; WATANABE, Y ; KAMEI, H ; MORITAKA, T ; SHIBAYAMA, T ; UEOKA, H ; GEMBA, K ; YONEI, T
Assuntos: Adult ; Aged ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Non-Small-Cell Lung - radiotherapy ; Cisplatin - administration & dosage ; Clinical Study ; Clinical Trials, Phase II as Topic ; Combined Modality Therapy ; Female ; Fluorouracil - administration & dosage ; Follow-Up Studies ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - pathology ; Lung Neoplasms - radiotherapy ; Male ; Medical sciences ; Middle Aged ; Neoplasm Staging ; Neoplasms, Second Primary - diagnosis ; Pneumology ; Survival Analysis ; Survivors ; Taxoids - administration & dosage ; Time Factors ; Tumors ; Tumors of the respiratory system and mediastinum
É parte de: British journal of cancer, 2006-11, Vol.95 (9), p.1142-1144
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
Descrição: Long-term cancer survivors risk development of second primary cancers (SPC). Vigilant follow-up may be required. We report outcomes of 92 patients who underwent chemoradiation for unresectable stage III non-small-cell lung cancer, with a median follow-up of 8.9 years. The incidence of SPC was 2.4 per 100 patient-years (95% confidence interval: 1.0-4.9).
Editor: Basingstoke: Nature Publishing Group
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer

TAKIGAWA, N ; KIURA, K ; TABATA, M ; SHINKAI, T ; HIRAKI, S ; TAKEMOTO, M ; KANAZAWA, S ; MATSUO, K ; TANIMOTO, M ; SEGAWA, Y ; WATANABE, Y ; KAMEI, H ; MORITAKA, T ; SHIBAYAMA, T ; UEOKA, H ; GEMBA, K ; YONEI, T

Basingstoke: Nature Publishing Group

Buscando em bases de dados remotas. Favor aguardar.